DK1778655T3 - 2-{-3-'2-(phenyl)-oxazol-4-ylmethoxy!-cyclohexylmethoxy}-propionsyrederivater som PPAR-ligander (peroxisomen-proliferator-aktiverede receptorer) til behandling af hyperlipidæmi og diabetes - Google Patents

2-{-3-'2-(phenyl)-oxazol-4-ylmethoxy!-cyclohexylmethoxy}-propionsyrederivater som PPAR-ligander (peroxisomen-proliferator-aktiverede receptorer) til behandling af hyperlipidæmi og diabetes

Info

Publication number
DK1778655T3
DK1778655T3 DK05772240T DK05772240T DK1778655T3 DK 1778655 T3 DK1778655 T3 DK 1778655T3 DK 05772240 T DK05772240 T DK 05772240T DK 05772240 T DK05772240 T DK 05772240T DK 1778655 T3 DK1778655 T3 DK 1778655T3
Authority
DK
Denmark
Prior art keywords
cyclohexylmethoxy
ylmethoxy
oxazol
hyperlipidemia
diabetes
Prior art date
Application number
DK05772240T
Other languages
Danish (da)
English (en)
Inventor
Heiner Glombik
Christian Stapper
Eugen Falk
Stefanie Keil
Hans-Ludwig Schaefer
Wolfgang Wendler
Stephanie Knieps
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Application granted granted Critical
Publication of DK1778655T3 publication Critical patent/DK1778655T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/4211,3-Oxazoles, e.g. pemoline, trimethadione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DK05772240T 2004-08-14 2005-07-30 2-{-3-'2-(phenyl)-oxazol-4-ylmethoxy!-cyclohexylmethoxy}-propionsyrederivater som PPAR-ligander (peroxisomen-proliferator-aktiverede receptorer) til behandling af hyperlipidæmi og diabetes DK1778655T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004039532A DE102004039532B4 (de) 2004-08-14 2004-08-14 Cyclohexyl-methyloxy substituierte Essigsäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
PCT/EP2005/008281 WO2006018115A1 (de) 2004-08-14 2005-07-30 2-{-3-`2 (phenyl) -oxazol-4 ylmethoxy!-cyclohexylmethoxy} - propionsäure derivate als ppar liganden (peroxisomen-proliferatoren-aktivierte rezeptoren) zur behandlung von hyperlipidämie und diabetes

Publications (1)

Publication Number Publication Date
DK1778655T3 true DK1778655T3 (da) 2009-08-24

Family

ID=35159900

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05772240T DK1778655T3 (da) 2004-08-14 2005-07-30 2-{-3-'2-(phenyl)-oxazol-4-ylmethoxy!-cyclohexylmethoxy}-propionsyrederivater som PPAR-ligander (peroxisomen-proliferator-aktiverede receptorer) til behandling af hyperlipidæmi og diabetes

Country Status (21)

Country Link
US (1) US7956077B2 (pt)
EP (1) EP1778655B1 (pt)
JP (1) JP2008509891A (pt)
KR (1) KR20070040813A (pt)
CN (1) CN101031553A (pt)
AR (1) AR050290A1 (pt)
AT (1) ATE430739T1 (pt)
AU (1) AU2005274492A1 (pt)
BR (1) BRPI0513999A (pt)
CA (1) CA2576545A1 (pt)
DE (2) DE102004039532B4 (pt)
DK (1) DK1778655T3 (pt)
ES (1) ES2326423T3 (pt)
IL (1) IL181010A0 (pt)
MX (1) MX2007000913A (pt)
PE (1) PE20060624A1 (pt)
PT (1) PT1778655E (pt)
SV (1) SV2006002191A (pt)
TW (1) TW200619211A (pt)
UY (1) UY29063A1 (pt)
WO (1) WO2006018115A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0617207A2 (pt) 2005-09-29 2011-07-19 Sanofi Aventis derivados de fenil-1,2,4-oxadiazolona, processos para sua preparação e seu uso como produtos farmacêuticos

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4436129B2 (ja) * 2001-08-31 2010-03-24 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ジアリールシクロアルキル誘導体、その製造法及びppar−活性剤としてのその使用
DE10308355A1 (de) * 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel

Also Published As

Publication number Publication date
ES2326423T3 (es) 2009-10-09
WO2006018115A1 (de) 2006-02-23
PE20060624A1 (es) 2006-07-27
CA2576545A1 (en) 2006-02-23
AU2005274492A1 (en) 2006-02-23
UY29063A1 (es) 2006-02-24
EP1778655A1 (de) 2007-05-02
US7956077B2 (en) 2011-06-07
TW200619211A (en) 2006-06-16
IL181010A0 (en) 2007-07-04
BRPI0513999A (pt) 2008-05-20
PT1778655E (pt) 2009-07-13
DE102004039532A1 (de) 2006-03-02
EP1778655B1 (de) 2009-05-06
AR050290A1 (es) 2006-10-11
DE502005007249D1 (de) 2009-06-18
MX2007000913A (es) 2007-04-16
DE102004039532B4 (de) 2006-09-21
SV2006002191A (es) 2006-07-07
KR20070040813A (ko) 2007-04-17
US20070197613A1 (en) 2007-08-23
JP2008509891A (ja) 2008-04-03
ATE430739T1 (de) 2009-05-15
CN101031553A (zh) 2007-09-05

Similar Documents

Publication Publication Date Title
DK1789403T3 (da) N-(phenyl-oxazol-4ylmethoxymethyl)-cyclohexyl-ravsyreamid derivater og beslægtede forbindelser som PPAR-ligander (peroxisom-proliferator-aktiverede receptorer) til behandling af hyperlipidæmi og diabetes
NO20054396D0 (no) 3-metyl-2-(3-(2-fenyl-oksazol-4-ylmetoksy)-cykloheksankarbonyl-amino)-smorsyrederivater og lignende forbindelser som PPAR-modulatorer til behandling av type 2 diabetes og aterosklerose
DK1651622T3 (da) Fremgangsmåde til fremstilling af 2-(quinoxalin-5-ylsulfonylamino)-benzamidforbindelser
DK1349843T3 (da) Thiazol- og oxazolderivater som aktivatorer af human peroxisom profilerator-aktiverede receptorer
ATE405260T1 (de) Thiazol- und oxazolderivaten als ppar modulatoren
DK1678185T3 (da) 2,3-dihydro-6-nitroimidazo[2,1-b]oxazolforbindelser til behandling af tuberkulose
DK1458672T3 (da) Substituerede phenylpropionsyrederivater som antagonister af human peroxisomproliferatoraktiveret receptor alfa (PPAR)
DK1701944T3 (da) 2-(amino-substituerede)-4-aryl-pyramidiner og relaterede forbindelser til behandling af inflammationssygdomme
ATE517097T1 (de) Thiazol- und oxazolsubstituierte arylamide
DK2059513T3 (da) Fremgangsmåde til fremstillingen af 1,2,4-oxadiazolbenzoesyrer
IL175310A0 (en) Phenoxyacetic acids derivatives useful as peroxisome proliferator-activated receptor (ppar) dual agonists
DK1924574T3 (da) Fremgangsmåde til syntese af 5-(methyl-1H-imidazol-1-yl)-3-(trifluormethyl)-benzenamin
SG130141A1 (en) Modulation of peroxisome proliferator-activated receptors
ATE525355T1 (de) 1-ä(4-äbenzoyl(methyl)aminoü-3- (phenyl)butylüazetidinderivate zur behandlung von gastrointestinalen erkrankungen 1
DK2300452T3 (da) 5 -[5- [2-(3,5 -(bis(trifluoromethyl)phenyl) -2 - methylpropanoylmethylamino ]-4 -(4-fluoro -2-methylphenyl)]-2-pyridinyl -2-alkyl -prolinamid som NK1 receptor antagonister
SI1539746T1 (sl) Spojine n-substituirane-1h-indol-5-propionske kisline kot agonisti ppar, ki so uporabne za zdravljenje diabetesa
DK1778655T3 (da) 2-{-3-'2-(phenyl)-oxazol-4-ylmethoxy!-cyclohexylmethoxy}-propionsyrederivater som PPAR-ligander (peroxisomen-proliferator-aktiverede receptorer) til behandling af hyperlipidæmi og diabetes
SG118360A1 (en) Modulation of peroxisome proliferator-activated receptors
DK1789402T3 (da) 2-{-3-2-(phenyl)-oxazol-4-ylmethoxymethyl-cyclohexylmethoxy)-propionsyrederivater som PPAR-ligander (peroxisomen-proliferator-aktiverede receptorer) til behandling af hyperlipidæmi og diabetes
DK1517883T3 (da) Ortho-substituerede benzoesyrederivater til behandling af insulinresistens
DK1517679T3 (da) Ortosubstituerede benzoesyrederivater til behandling af insulinresistens
CL2007001691A1 (es) Metodo para hacer n-hidroxi-3-(4(((2-(2-metil-1h-indol-3-il)etil)amino)metil)fenil)-2e-2-propenamida.
FI20045034A (fi) Laite pienpuun keräämiseksi
SE0400574D0 (sv) A novel pharmaceutical composition for the treatment of psoriasis
TH88508B (th) อนุพันธ์ 2-(เบนซิมิดาซอล-1-อิล)-อะเซทาไมด์ไบแซริล